Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcutis Biotherapeutics (ARQT)
NASDAQ:ARQT
RESEARCH TOOLSreports
Holding ARQT?
Track your performance easily
ARQT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.96 - $15.79
Previous Close$14.99
Volume1.27M
Average Volume (3M)2.07M
Market Cap
$1.75B
Enterprise Value$1.63B
Total Cash (Recent Filing)$330.56M
Total Debt (Recent Filing)$208.18M
Price to Earnings (P/E)―
Beta2.26
Next Earnings
Mar 04, 2025EPS Estimate
-$0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.79
Shares Outstanding117,044,591
10 Day Avg. Volume2,591,124
30 Day Avg. Volume2,074,464
Standard Deviation0.28
R-Squared0.06
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)11.19
Price to Sales (P/S)12.63
Price to Cash Flow (P/CF)-12.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue11.75
Enterprise Value/Gross Profit29.84
Enterprise Value/Ebitda-9.29
Forecast
1Y Price Target
$19.00Price Target Upside26.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Arcutis Biotherapeutics News
PremiumCompany Announcements
Arcutis Biotherapeutics Reports Strong Q3 2024 Results
Bulls Say, Bears Say
Bulls Say
Analyst ConfidenceThe analyst maintains an 'Outperform' rating for Arcutis Biotherapeutics Inc, indicating confidence in the company's growth prospects.
Market PositionZoryve is currently the leader in branded anti-inflammatory topical class, addressing the 4.5M commercially insured PsO, seb derm, and AD patients.
Product PerformanceZoryve franchise sales of $44.5MM exceeded consensus by 20%, driven by strong volume growth.
Bears Say
Market ConditionsRecent prescription growth was previously hindered by adverse weather conditions, affecting market performance.
Prescription DeclineThe Zoryve franchise experienced a significant decrease in prescription growth, with a 25.6% drop in total prescriptions and a 30.5% decline in new prescriptions.
Product PerformanceZoryve Foam 0.3% had a 26.5% decline in total prescriptions and a 32.9% decrease in new prescriptions.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ARQT FAQ
What was Arcutis Biotherapeutics’s price range in the past 12 months?
Arcutis Biotherapeutics lowest stock price was $2.96 and its highest was $15.79 in the past 12 months.
What is Arcutis Biotherapeutics’s market cap?
Currently, no data Available
When is Arcutis Biotherapeutics’s upcoming earnings report date?
Arcutis Biotherapeutics’s upcoming earnings report date is Mar 04, 2025 which is in 69 days.
How were Arcutis Biotherapeutics’s earnings last quarter?
Arcutis Biotherapeutics released its earnings results on Nov 06, 2024. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.417 by $0.087.
Is Arcutis Biotherapeutics overvalued?
According to Wall Street analysts Arcutis Biotherapeutics’s price is currently Undervalued.
Does Arcutis Biotherapeutics pay dividends?
Arcutis Biotherapeutics does not currently pay dividends.
What is Arcutis Biotherapeutics’s EPS estimate?
Arcutis Biotherapeutics’s EPS estimate is -$0.28.
How many shares outstanding does Arcutis Biotherapeutics have?
Arcutis Biotherapeutics has 117,044,590 shares outstanding.
What happened to Arcutis Biotherapeutics’s price movement after its last earnings report?
Arcutis Biotherapeutics reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.417. Following the earnings report the stock price went up 7.66%.
Which hedge fund is a major shareholder of Arcutis Biotherapeutics?
Among the largest hedge funds holding Arcutis Biotherapeutics’s share is Gilder Gagnon Howe & Co LLC.. It holds Arcutis Biotherapeutics’s shares valued at 33M.
---
Company Description
Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.
---
ARQT Company Deck
---
ARQT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call showcased significant growth in ZORYVE portfolio sales and gross-to-net improvements, indicating a strong financial performance. While there were some challenges, such as delays in Medicare Part D coverage and minor hurricane impacts, the overall outlook remains positive with strong cash management and expansion in Medicaid coverage.Read More>---
ARQT Stock 12 Month Forecast
Average Price Target
$19.00
▲(26.75% Upside)
Technical Analysis
Best Analysts Covering ARQT
1 Year
1 Year Success Rate
9/18 ratings generated profit
1 Year Average Return
+43.60%
reiterated a buy rating 2 months ago
Copying Vikram Purohit's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +43.60% per trade.
---